Attached files
file | filename |
---|---|
EX-99.2 - EX-99.2 - Zynerba Pharmaceuticals, Inc. | a15-21328_1ex99d2.htm |
EX-99.1 - EX-99.1 - Zynerba Pharmaceuticals, Inc. | a15-21328_1ex99d1.htm |
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of Earliest Event Reported): October 20, 2015
ZYNERBA PHARMACEUTICALS, INC.
(Exact Name of Issuer as Specified in Charter)
Delaware |
|
001-37526 |
|
26-0389433 |
(State or Other Jurisdiction of |
|
(Commission |
|
(I.R.S. Employer |
80 W. Lancaster Avenue, Suite 300
Devon, PA 19333
(Address of Principal Executive Offices)
(484) 581-7505
(Registrants Telephone Number, Including Area Code)
Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act
Item 7.01 Regulation FD Disclosure
On October 20, 2015, Zynerba Pharmaceuticals, Inc. (the Company) issued a press release announcing the initiation of a Phase 1 clinical trial for its ZYN002 cannabidiol gel. A copy of this press release is attached hereto as Exhibit 99.1.
Attached as Exhibit 99.2 and furnished for purposes of Regulation FD is a presentation the Company will use at the Bio Investor Forum on October 20, 2015, at 8:30 a.m. PT, and may use from time to time in other presentations or discussions with investors, analysts and other parties. A live webcast of the presentation may be accessed through the following link http://www.veracast.com/webcasts/bio/investorforum2015/86102126746.cfm or via the Companys website (www.zynerba.com) by selecting Investor Relations then News and Events followed by Webcast.
The information in this Item 7.01 (including Exhibits 99.1 and 99.2) is being furnished solely to satisfy the requirements of Regulation FD and shall not be deemed to be filed for purposes of Section 18 of the Securities Exchange Act of 1934 (the Exchange Act) or otherwise subject to the liabilities of that Section, nor shall it be deemed to be incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits
EXHIBIT |
|
DESCRIPTION |
|
|
|
99.1 |
|
Press Release, dated October 20, 2015. |
99.2 |
|
Zynerba Pharmaceuticals, Inc. Presentation. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
ZYNERBA PHARMACEUTICALS, INC. | ||
|
|
| |
Date: October 20, 2015 |
By: |
/s/ Suzanne Hanlon | |
|
|
Name: |
Suzanne Hanlon |
|
|
Title: |
Secretary, General Counsel and Vice President, Human Resources |